The Spectranetics

Manufacturing · Colorado, United States · 960 Employees

Spectranetics is now a part of Philips, a leading health technology company focused on improving peoples health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Follow us atwww.linkedin.com/company/philips.Read More

View Company Info for Free

Who is The Spectranetics

Headquarters

9965 Federal Dr, Colorado Springs, Colorado, 80921, United States

Phone Number

(719) 633-8333

Website

www.spectranetics.com

Revenue

$284.6M

Industry

Manufacturing General

Manufacturing

Is this data correct?

View contact profiles from The Spectranetics

Popular SearchesTHE SPECTRANETICS CorpSpectranetics LLCSpectraneticsSpectranetics CorpSpectranetics IncSIC Code 38,384NAICS Code 33,339Show More

Top Competitors of The Spectranetics

Mindray North America
405
$93.9M
1
Cardiovascular Systems Inc
700
$175.5M
2
Lumenis Ltd
1,500
$363M
3
AngioDynamics Inc
760
$303.3M
4
Cynosure Inc
1,400
$351M
5
Amsino International Inc
1,901
$516.3M
6

The Spectranetics Org Chart

John Schulte

Chief Executive Officer

Phone

James Andrews

Chief Financial Officer

Phone

View Email Formats for The Spectranetics

The Spectranetics Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateJan 20, 1992

RoundStock Issuance/Offering

Amount$33.8M

Investors

$33.8M

Total Funding Amount

$33.8M

Most Recent Funding Amount

Number of Funding Rounds

Acquisitions & Subsidiaries

Jul 18, 2022

VISICU

Jul 18, 2022

Philips TV Ireland

Jul 18, 2022

Cardiopulmonary

Jul 18, 2022

Capsule Technologies

Jul 18, 2022

Capsule Technologies

Jul 18, 2022

Philips India

See More Acquisitions & Subsidiaries

The Spectranetics Tech Stack

Linux

Linux Foundation

Salesforce

The R Foundation

Python

See more technologies

Top Companies in United States

The Spectranetics News & Media

Upstream Peripheral's GoBack CTO Catheter Aces its Exam | Business Wire
Upstream Peripheral Technologies announced today that its CTO-busting GoBack® Catheter for crossing and reentry was proven very effective for patients
Jan 4, 2022
www.businesswire.com
Upstream Peripheral’s GoBack CTO Catheter Aces its Exam
CAESAREA, Israel & TAMPA, Fla.--(BUSINESS WIRE)--Upstream Peripheral Technologies announced today that its CTO-busting GoBack® Catheter for crossing and reentry was proven very effective for patients undergoing complex revascularizations in lower limb arteries. The findings are based on a peer-reviewed study published in the Journal of Endovascular Therapy. In a single-center retrospective study led by Professor Andrej Schmidt (University Hospital, Leipzig), researchers reviewed outcomes of 100
Jan 4, 2022
www.businesswire.com
Philips showcases integrated vascular solutions at VEITH 2017
AMSTERDAM and NEW YORK, Nov. 13, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it will be showcasing its integrated vascular solutions comprising interventional X-ray systems, diagnostic and therapeutic devices, planni...
Nov 13, 2017
www.prnewswire.com
Spectranetics Announces Fundamental Change, Make-Whole Adjustment Event, Share Exchange Event and Supplemental Indenture for 2.625% Convertible Senior Notes due 2034
COLORADO SPRINGS, Colo., Aug. 10, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”), a developer and manufacturer of single-use medical devices used in minimally invasive procedures within the cardiovascular system, today announced the occurrence of a Fundamental Change, Make-Whole Adjustment Event and Share Exchange Event, and the execution and delivery of a Second Supplemental Indenture, dated August 9, 2017, with respect the Company’s 2.625% Convertible Seni
Aug 10, 2017
phx.corporate-ir.net
Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million
COLORADO SPRINGS, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”) today reported financial results for the three months ended June 30, 2017. Highlights of the quarter, all compared with the three months ended June 30, 2016, include: Revenue of $74.7 million increased 10% (11% constant currency1) Vascular Intervention revenue of $51.0 million increased 10% (11% constant currency1) Lead Management revenue of $19.7 million increased 11% (12% cons
Aug 3, 2017
phx.corporate-ir.net